Literature DB >> 961588

Cardiovascular effects of ajmaline.

K Obayashi, K Nagasawa, W J Mandel, J K Vyden, W W Parmley.   

Abstract

Ajmaline, a rauwolfia derivative, has been found to possess potent antiarrhythmic effects. The present study has been designed to define the cardiovascular effects of this drug. Hemodynamic studies performed in anesthetized and conscious dogs demonstrated no significant changes in measured hemodynamic parameters at doses equal to or less than 2 mg. per kilogram. Studies in isolated papillary muscle demonstrated no negative inotropic effects until concentrations of 1 X 10(-4). Disparate results were obtained with regard to heart rate reflecting the state of autonomic tone. Electrophysiologic studies in both anesthetized and conscious dogs demonstrated a significant depression of intraventricular conduction with no significant effect on AV nodal conduction; ventricular automaticity was not affected. Ajmaline did not alter digitalis-induced AV nodal conduction prolongation. However, ajmaline dramatically altered or abolished ventricular arrhythmias secondary to acute ischemia. In conclusion, these studies demonstrate that ajmaline specifically depresses intraventricular conduction, suggesting that this drug would be particularly effective in the treatment of re-entrant ventricular arrhythmias.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 961588     DOI: 10.1016/s0002-8703(76)80049-x

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

Review 1.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

Review 2.  Adverse effects of antiarrhythmic drugs.

Authors:  J B Schwartz; D Keefe; D C Harrison
Journal:  Drugs       Date:  1981-01       Impact factor: 9.546

3.  The ajmaline test as a method to disclose latent experimental Chagas' heart disease.

Authors:  R B Bestetti; E G Soares; V N Sales-Neto; J S Oliveira
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

4.  Acute haemodynamic effects of ajmaline and prajmaline in patients with coronary heart disease.

Authors:  E Sowton; I D Sullivan; J C Crick
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Pharmacokinetics and antiarrhythmic activity of ajmaline in rats subjected to coronary artery occlusion.

Authors:  Y Hashimoto; R Hori; K Okumura; M Yasuhara
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

6.  Effects of oral prajmaline bitartrate on exercise test responses in patients with coronary artery disease.

Authors:  C E Handler; A Kritikos; I D Sullivan; A Charalambakis; E Sowton
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 7.  Role of Provocable Brugada ECG Pattern in The Correct Risk Stratification for Major Arrhythmic Events.

Authors:  Nicolò Martini; Martina Testolina; Gian Luca Toffanin; Rocco Arancio; Luca De Mattia; Sergio Cannas; Giovanni Morani; Bortolo Martini
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.